- Home
- ADT vs NUVL Comparison
ADT vs NUVL Comparison
Compare ADT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- NUVL
- Stock Information
- Founded
- ADT 1874
- NUVL 2017
- Country
- ADT United States
- NUVL United States
- Employees
- ADT N/A
- NUVL N/A
- Industry
- ADT Diversified Commercial Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ADT Consumer Discretionary
- NUVL Health Care
- Exchange
- ADT Nasdaq
- NUVL Nasdaq
- Market Cap
- ADT 6.5B
- NUVL 5.6B
- IPO Year
- ADT 2018
- NUVL 2021
- Fundamental
- Price
- ADT $8.09
- NUVL $70.32
- Analyst Decision
- ADT Buy
- NUVL Strong Buy
- Analyst Count
- ADT 3
- NUVL 10
- Target Price
- ADT $9.07
- NUVL $113.10
- AVG Volume (30 Days)
- ADT 21.3M
- NUVL 583.7K
- Earning Date
- ADT 04-24-2025
- NUVL 05-08-2025
- Dividend Yield
- ADT 2.72%
- NUVL N/A
- EPS Growth
- ADT 10.20
- NUVL N/A
- EPS
- ADT 0.53
- NUVL N/A
- Revenue
- ADT $4,898,446,000.00
- NUVL N/A
- Revenue This Year
- ADT $5.32
- NUVL N/A
- Revenue Next Year
- ADT $5.00
- NUVL N/A
- P/E Ratio
- ADT $12.36
- NUVL N/A
- Revenue Growth
- ADT 5.28
- NUVL N/A
- 52 Week Low
- ADT $6.10
- NUVL $61.80
- 52 Week High
- ADT $8.39
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ADT 59.18
- NUVL 35.57
- Support Level
- ADT $7.68
- NUVL $71.95
- Resistance Level
- ADT $8.27
- NUVL $77.93
- Average True Range (ATR)
- ADT 0.19
- NUVL 3.04
- MACD
- ADT 0.04
- NUVL -0.16
- Stochastic Oscillator
- ADT 81.25
- NUVL 24.64
About ADT ADT Inc.
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. It offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. The company segments include Consumer and Small Business (CSB), Commercial, and Solar. It generates maximum revenue from the Commercial segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.